BHC

Bausch Health Companies Inc.

Fundamental data last updated:June 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NYSE

County of HQ

CA

Next Earnings Date

07/29/2026

Business Summary

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

 


VALUATION

P/E

-1.70

Market Cap ($M USD)

$2.02B

Forward P/E

1.76

PEG

0.01

PRICE TO SALES

0.19

PRICE TO BOOK

-0.98

EV / EBITDA

5.95

5-Year Average P/E

Free Cash Flow Yield

48.97%

DCF Value

$183.09

Graham Number

N/A

Price to FCF

2.04

EV to FCF

21.74

Earnings Yield

-58.98%

FCF Yield

48.97%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.19

Next Year EPS Growth Estimate

$3.08

Next Year Revenue Growth Estimate

$955.56B

Return on Equity (ROE)

120.75%

FREE CASH FLOW

Operating Margin

22.91%

Debt-to-Equity

-38.35

Piotroski F-Score

5

Altman Z-Score

0.24

Return on Invested Capital (ROIC)

12.11%

Current Ratio

1.32

Quick Ratio

0.97

Net Debt to EBITDA

5.39

Interest Coverage

1.43

Gross Profit margin

61.67%

FCF PER SHARE

$2.65

REVENUE PER SHARE

$28.31

Gainseekers Quantitative Analysis

Summary

Bausch Health Companies Inc. presents a perplexing valuation scenario. Recent pricing indicated the stock traded dramatically below its DCF value, suggesting a potential deep value opportunity. However, the negative Price/Book ratio and alarming Altman Z-score highlight significant financial distress, raising red flags about its long-term viability. The Forward P/E suggests optimism for future earnings, yet the negative Earnings Yield underscores current profitability challenges. Investors must weigh these conflicting signals carefully.

AI Exposure / Tech Reliance

Operating within the healthcare sector, Bausch Health is positioned to leverage AI advancements in drug development and personalized medicine. The specialty and generic drug industry is ripe for technological integration, potentially enhancing efficiency and innovation. However, the company's ability to adapt will depend on strategic investments and partnerships.

The Bull Case

For the value-driven investor, Bausch Health offers compelling reasons to buy. The robust ROIC of 12.11% indicates efficient capital allocation, while a strong FCF Yield of 46.08% suggests substantial cash generation potential. With a Piotroski F-Score of 5, the company demonstrates moderate financial health, and its operating margin of 22.91% reflects solid pricing power. These metrics paint a picture of a company capable of delivering shareholder value amidst market volatility.

The Bear Case

Despite some strengths, Bausch Health faces daunting structural risks. The negative Price/Book ratio and high Net Debt to EBITDA ratio of 5.39 signal financial instability. The company's Earnings Yield is deeply negative, reflecting current profitability issues. Additionally, the Altman Z-score of 0.24 indicates a high risk of financial distress, making it a risky bet for conservative investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$8.00

Institutional Ownership %

1-Year Beta

0.42

Insider Buying % (6 Mo)

Distance to 52-Week High

60.63%

Distance to 52-Week Low

18.48%

EARNINGS SURPRISE %

-3.70%

50-DAY SMA

$5.46

200-DAY SMA

$6.29

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.